Across TCGA pan-cancer cohorts, SH2D7 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SH2D7 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher SH2D7 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SH2D7 expression acts as an unfavorable survival marker.

SARC and SKCM are the cancer types where SH2D7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	DFS	Median	All	0.134	0.613	.006	6	view →
SKCM	DFS	Median	IV	0.036	0.433	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: SH2D7 tumor-vs-normal RNA expression · all SH2D7 data types